Skip to content

Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

Compare within a sector
MetricNVSNovartis AGAZNAstraZeneca PLCMRKMerck & Co.
Snapshot
Price$140.87$157.00$143.90
Market cap$261.56B$284.73B$319.99B
Valuation
P/E19.5x24.1x39.6x
Forward P/E17.9x18.1x56.6x
Growth
Revenue growth5.8%9.9%2.9%
EPS growth9.3%33.7%-48.3%
Profitability
Net margin24.1%17.2%13.6%
ROE31.7%22.3%17.9%
Balance sheet & cash
Debt / equity0.77x0.61x0.94x
Free cash flow yield4.2%3.1%2.9%
Dividend yield2.9%1.7%3.0%
Verdict
Investment ratingFavorable· 67Favorable· 68Weak· 40

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

YearNVStoday $141AZNtoday $157MRKtoday $144
2027$115.45 – $169.32+20% CAGR$157.44 – $230.92+47% CAGR$110.08 – $161.46+12% CAGR
2028$126.15 – $185.02+15% CAGR$210.52 – $308.76+40% CAGR$112.29 – $164.68+7% CAGR
2029$137.84 – $202.17+13% CAGR$281.48 – $412.84+38% CAGR$114.53 – $167.98+5% CAGR
2030$150.62 – $220.91+12% CAGR$376.37 – $552.01+37% CAGR$116.82 – $171.34+4% CAGR
2031$164.58 – $241.39+11% CAGR$503.25 – $738.09+36% CAGR$119.16 – $174.76+4% CAGR
5-yr CAGR3.2% – 11.4%26.2% – 36.3%-3.7% – 4.0%